RICHARD CAIN: Open Payments
NPI 1700236510 · LIVINGSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,211 in 63 payments from 15 companies in 2025. Trend: 2023 $1,410 · 2024 $1,468 · 2025 $1,211
Food & beverage: $1,211
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $225 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $192 |
| Novo Nordisk Inc | 9 | $164 |
| GlaxoSmithKline, LLC. | 7 | $144 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $82 |
| Viatris Specialty LLC | 4 | $79 |
| Amgen Inc. | 3 | $57 |
| ABBVIE INC. | 3 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $49 |
| Inspire Medical Systems, Inc. | 2 | $48 |
Products named: Kerendia, TRELEGY ELLIPTA, AIRSUPRA, BREZTRI, Rybelsus, XIFAXAN, YUPELRI, Ozempic.
Industry payments across TX — which companies pay providers there.
